Cart
sales@molnova.com
Rilopirox
CAS No. 104153-37-9
Rilopirox( —— )
Catalog No. M34131 CAS No. 104153-37-9
Rilopirox (HOE 351) initiated a novel antifungal compound for the study of mucosal Candida infections, lichen planus and seborrheic dermatitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRilopirox
-
NoteResearch use only, not for human use.
-
Brief DescriptionRilopirox (HOE 351) initiated a novel antifungal compound for the study of mucosal Candida infections, lichen planus and seborrheic dermatitis.
-
DescriptionRilopirox (HOE 351) initiated a novel antifungal compound for the study of mucosal Candida infections, lichen planus and seborrheic dermatitis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetAntifungal
-
RecptorAntifungal
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number104153-37-9
-
Formula Weight357.79
-
Molecular FormulaC19H16ClNO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=C(C=C(N1O)COC2=CC=C(OC3=CC=C(Cl)C=C3)C=C2)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Gamitrinib TPP hexaf...
Gamitrinib TPP hexafluorophosphate is a mitochondrial-targeted HSP90 inhibitor with anticancer activity, which can regulate cell cycle and cell homeostasis and can be used to study cancer, neurodegenerative diseases and viral infections.
-
Dihydrocapsaicin
Dihydrocapsaicin is isolated from Capsicum fruit. Capsaicin is the primary active component of the heat and pain-eliciting lipid soluble fraction of the Capsicum pepper.
-
Asebogenin
Asebogenin is a compound fractionated from Salvia miltiorrhiza with antifungal activity, inhibition of GPVI-induced platelet reactions, and inhibition of NET formation induced by pro-inflammatory stimuli.
